Literature DB >> 25553476

Rational clinical trial design for antibody mediated renal allograft injury.

Shaifali Sandal1, Martin S Zand1.   

Abstract

Antibody mediated renal allograft rejection is a significant cause of acute and chronic graft loss. Recent work has revealed that AMR is a complex processes, involving B and plasma cells, donor-specific antibodies, complement, vascular endothelial cells, NK cells, Fc receptors, cytokines and chemokines. These insights have led to the development of numerous new therapies, and adaptation of others originally developed for treatment of hemetologic malignancies, autoimmune and complement mediated conditions. Here we review emerging insights into the pathophysiology of AMR as well as current and emerging therapies for both acute and chronic AMR. Finally, we discuss rational clinical trial design in light of antibody and B cell immunobiology, as well as appropriate efficacy metrics to identify robust protocols and therapeutic agents.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25553476      PMCID： PMC4609572          DOI： 10.2741/4334

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN： 2768-6698


  109 in total

Review 1.  Proteasome inhibition for antibody-mediated allograft rejection.

Authors:  Basma Sadaka; Rita R Alloway; Adele R Shields; Nicole M Schmidt; E Steve Woodle
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

2.  Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports.

Authors:  Eric Siskind; Madhu Bhaskaran; Fouad Boctor; Kavin Shah; Ernesto Molmenti
Journal:  Int J Angiol       Date:  2012-06

3.  Plasma exchange in acute renal allograft rejection: is a controlled trial really necessary?

Authors:  D Power; A Nicholls; N Muirhead; A M MacLeod; J Engeset; G R Catta; N Edward
Journal:  Transplantation       Date:  1981-08       Impact factor: 4.939

Review 4.  Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients.

Authors:  S C Jordan; M Toyoda; J Kahwaji; A A Vo
Journal:  Am J Transplant       Date:  2011-01-10       Impact factor: 8.086

5.  Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups.

Authors:  B Sis; M Mengel; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; W M Baldwin; E R Bracamonte; V Broecker; F Cosio; A J Demetris; C Drachenberg; G Einecke; J Gloor; D Glotz; E Kraus; C Legendre; H Liapis; R B Mannon; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; E R Rodriguez; D Seron; S Seshan; M Suthanthiran; B A Wasowska; A Zachary; A Zeevi
Journal:  Am J Transplant       Date:  2010-01-29       Impact factor: 8.086

6.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

7.  The pathogenesis of acute allograft dysfunction in desensitized renal transplant recipients.

Authors:  N Singh; Q Sun; T Nadasdy; P Adams; N R Dipaola; T Pesavento; H Winters; A Satoskar; Z Yu; M Henry; G A Hadley; R P Pelletier
Journal:  Clin Transplant       Date:  2012 Jul-Aug       Impact factor: 2.863

8.  Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Authors:  Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

9.  High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.

Authors:  B Tanriover; S E Wright; S V Foster; K S Roush; J A Castillo-Lugo; K Fa; F L Levy; A Mejia
Journal:  Transplant Proc       Date:  2008-12       Impact factor: 1.066

10.  Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.

Authors:  Christopher Lawrence; Michelle Willicombe; Paul A Brookes; Eva Santos-Nunez; Retesh Bajaj; Terry Cook; Candice Roufosse; David Taube; Anthony N Warrens
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939
View more
  3 in total

Review 1.  Potential Roles for C1 Inhibitor in Transplantation.

Authors:  Mel Berger; William M Baldwin; Stanley C Jordan
Journal:  Transplantation       Date:  2016-07       Impact factor: 4.939

2.  CD56+CD57+ infiltrates as the most predominant subset of intragraft natural killer cells in renal transplant biopsies with antibody-mediated rejection.

Authors:  Hey Rim Jung; Mi Joung Kim; Yu-Mee Wee; Jee Yeon Kim; Monica Young Choi; Ji Yoon Choi; Hyunwook Kwon; Joo Hee Jung; Yong Mee Cho; Heounjeong Go; Sang-Yeob Kim; Yeon-Mi Ryu; Yun Jae Kim; Young Hoon Kim; Duck Jong Han; Sung Shin
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379

3.  Identification of Biomarkers for Predicting Allograft Rejection following Kidney Transplantation Based on the Weighted Gene Coexpression Network Analysis.

Authors:  Li-Jun Wang; Xiao-Bo Ma; Hong-Ying Xia; Xun Sun; Lu Yu; Qian Yang; Zong-Qiang Hu; Yong-Heng Zhao; Wei Hu; Jiang-Hua Ran
Journal:  Biomed Res Int       Date:  2021-07-29       Impact factor: 3.246
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.